Premium
Injectable rhBMP‐2‐loaded chitosan hydrogel composite: Osteoinduction at ectopic site and in segmental long bone defect
Author(s) -
Luca Ludmila,
Rougemont AnneLaure,
Walpoth Beat H.,
Boure Ludovic,
Tami Andrea,
Anderson James M.,
Jordan Olivier,
Gurny Robert
Publication year - 2011
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.32957
Subject(s) - chitosan , materials science , bone morphogenetic protein 2 , biomedical engineering , bone formation , human bone , composite number , bone morphogenetic protein , bone healing , surgery , composite material , medicine , chemistry , in vitro , biochemistry , gene
Carriers for bone morphogenetic protein‐2 (BMP‐2) used in clinical practice still suffer from limitations such as insufficient protein retention. In addition, there is a clinical need for injectable carriers. The main objective of this study was to assess bone forming ability of rhBMP‐2 combined either with chitosan hydrogel (rhBMP‐2/CH) or chitosan hydrogel containing β‐tricalcium phosphate (β‐TCP) (rhBMP‐2/CH/TCP). Formulations were first compared in a rat ectopic intramuscular bone formation model, and the optimal formulation was further evaluated in healing of 15‐mm critical size defect in the radius of a rabbit. Three weeks after injection ectopically formed bone was analyzed by microcomputerized tomography (micro‐CT) and histology. Significantly higher (4.7‐fold) mineralized bone formation was observed in the rhBMP‐2/CH/TCP group compared to rhBMP‐2/CH group. In a pilot study, defect in a rabbit radius treated with rhBMP‐2/CH/TCP showed incomplete regeneration at 8 weeks with composite leakage from the defect, indicating the need for formulation refinement when segmental defect repair is foreseen. © 2010 Wiley Periodicals, Inc. J Biomed Mater Res Part A:, 2010.